Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ALAMEDA, Calif., Feb. 6, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, today announced...
-
ALAMEDA, Calif., Feb. 6, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) today announced findings from a safety and tolerability study with AV411 (ibudilast), an oral therapy intended for the...
-
ALAMEDA, Calif., Dec. 7, 2006 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today...
-
ALAMEDA, Calif., Dec. 6, 2006 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) today announced findings from a Phase I clinical trial for AV650 (tolperisone), an oral therapy intended for the treatment...
-
ALAMEDA, Calif., Nov. 1, 2006 (PRIMEZONE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that...
-
ALAMEDA, Calif., Oct. 25, 2006 (PRIMEZONE) -- Avigen, Inc. (Nasdaq:AVGN) today reported financial results for the three and nine months ended September 30, 2006. At September 30, 2006, Avigen had...